Health Economics›Breast cancer›Neoadjuvant therapy postmenopausal

Neoadjuvant therapy postmenopausal

Breast cancer · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Anastrozole and Palbociclib Variant #02	ER	R 10 015	28d	~5.7 mo	—	~2	~R 20 029 PFS proxy · indirect	1
Doxorubicin and Paclitaxel (AT) Variant #01	ER	R 1 609	21d	—	~25.3 mo	~9	~R 13 972 PFS proxy · indirect	1
Exemestane monotherapy Variant #01	ER	R 886	90d	~3.8 mo	~45.1 mo	~2	~R 1 771 PFS proxy · indirect	10
Letrozole monotherapy Variant #01	ER	R 371	28d	~14.5 mo	~51.3 mo	~2	~R 742 PFS proxy · indirect	16
Anastrozole monotherapy Variant #01	ER	R 159	28d	~13.8 mo	~42.7 mo	~2	~R 318 PFS proxy · indirect	12
Tamoxifen monotherapy Variant #01	ER	R 137	28d	~6.8 mo	~23.8 mo	~130	~R 17 763 PFS proxy · indirect	9

6 of 6 regimens shown